Recent developments in application of single-cell RNA sequencing in the tumour immune microenvironment and cancer therapy

PH Li, XY Kong, YZ He, Y Liu, X Peng, ZH Li… - Military Medical …, 2022 - Springer
The advent of single-cell RNA sequencing (scRNA-seq) has provided insight into the tumour
immune microenvironment (TIME). This review focuses on the application of scRNA-seq in …

Uncovering the complex role of interferon-gamma in suppressing type 2 immunity to cancer

AA Bhat, A Goyal, R Thapa, I Kazmi, SI Alzarea… - Cytokine, 2023 - Elsevier
Cancer involves cells' abnormal growth and ability to invade or metastasize to different body
parts. Cancerous cells can divide uncontrollably and spread to other areas through the …

Remodeled tumor immune microenvironment (TIME) parade via natural killer cells reprogramming in breast cancer

MM Elanany, D Mostafa, NM Hamdy - Life sciences, 2023 - Elsevier
Breast cancer (BC) is the main cause of cancer-related mortality among women globally.
Despite substantial advances in the identification and management of primary tumors …

Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy

S Loizides, A Constantinidou - Frontiers in genetics, 2023 - frontiersin.org
Triple negative breast cancer (TNBC) is a biologically diverse subtype of breast cancer
characterized by genomic and transcriptional heterogeneity and exhibiting aggressive …

Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer

S Liu, X Zhang, W Wang, X Li, X Sun, Y Zhao, Q Wang… - Molecular Cancer, 2024 - Springer
Metabolic alterations, a hallmark of cancer, enable tumor cells to adapt to their environment
by modulating glucose, lipid, and amino acid metabolism, which fuels rapid growth and …

Understanding drug sensitivity and tackling resistance in cancer

JW Tyner, F Haderk, A Kumaraswamy, LB Baughn… - Cancer research, 2022 - AACR
Decades of research into the molecular mechanisms of cancer and the development of
novel therapeutics have yielded a number of remarkable successes. However, our ability to …

[HTML][HTML] Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy

K Liu, Q Sun, Q Liu, H Li, W Zhang, C Sun - Biomedicine & …, 2022 - Elsevier
The rise of cancer immunotherapy, particularly the use of immune checkpoint inhibitors
(ICIs), has significantly changed the clinical treatment paradigm for patients with cancer. The …

The role of MUC1 in renal cell carcinoma

M Milella, M Rutigliano, F Lasorsa, M Ferro, R Bianchi… - Biomolecules, 2024 - mdpi.com
Mucins are a family of high-molecular-weight glycoproteins. MUC1 is widely studied for its
role in distinct types of cancers. In many human epithelial malignancies, MUC1 is frequently …

Addiction of cancer stem cells to MUC1-C in triple-negative breast cancer progression

N Yamashita, D Kufe - International Journal of Molecular Sciences, 2022 - mdpi.com
Triple-negative breast cancer (TNBC) is an aggressive malignancy with limited treatment
options. TNBC progression is associated with expansion of cancer stem cells (CSCs). Few …

MUC1-C dictates PBRM1-mediated chronic induction of interferon signaling, DNA damage resistance, and immunosuppression in triple-negative breast cancer

N Yamashita, Y Morimoto, A Fushimi, R Ahmad… - Molecular Cancer …, 2023 - AACR
Abstract The polybromo-1 (PBRM1) chromatin-targeting subunit of the SWI/SNF PBAF
chromatin remodeling complex drives DNA damage resistance and immune evasion in …